Table 5.
Comparison of Baseline Characteristics of Omega-3 Studies for the Treatment of Dry Eye Disease.
| DREAM© | Epitropoulos 2016 [17] | Bhargava 2015 [73] | Bhargava 2016 [40] (Current Eye Research) | Bhargava 2016 [41] (Eye & Contact Lens) | |
|---|---|---|---|---|---|
| Daily omega-3 dose (mg) | 3000 | 2240 | 600 | 1200 | 2400 |
| Sample size | 535 | 105 | 456 | 130 | 522 |
| Duration of study | 12 months | 3 months | 3 months | 6 months | 45 days |
| Age, yrs. (mean) | 58.0 ± 13.2 | 56.8 ± 17.0 | 23.3 ± 5.2 | 48.3 ± 4.2 | 29.3 ± 4.9 |
| OSDI Symptom Score (mean) | 44.4 ± 14.2 | 29.8 ± 21.1 | 7.7 ± 2.3a | 8.9 ± 2.5a | 7.9 ± 2.3a |
| Corneal staining (mean) | 3.9 ± 2.7b | 1.4 ± 1.1c | N/A | N/A | N/A |
| Conjunctival staining (mean) | 3.0 ± 1.4d | N/A | N/A | N/A | N/A |
| Tear film breakup time, sec (mean) | 3.1 ± 1.5 | 4.7 ± 2.6 | 11.6 ± 1.8 | 9.4 ± 2.0 | 8.8 ± 2.0 |
| Schirmer test, mm/5 min (mean) | 9.6 ± 6.5 | 11.2 ± 7.5 | 20.0 ± 4.5 | 13.4 ± 5.1 | 15.8 ± 6.3 |
a
Symptoms assessed by the dry eye questionnaire and scoring system (DESS) 0 to 18 (0: no symptoms, 18: severe symptoms).
b
National Eye Institute [NEI]/industry-recommended guidelines (0: no staining, 15: severe staining).
c
Oxford staining scale 0 to 5 (0: no staining, 5: severe staining).
d
Modified NEI/industry-recommended scale (0: no staining, 6: severe staining).